Affymetrix to Webcast Investor Day 2009.SANTA CLARA Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. , Calif. -- Affymetrix Inc., (Nasdaq:AFFX) today announced that it will webcast the company's Investor Day 2009 conference the morning of Wednesday, June 3, 2009. The event will be held at the Nasdaq MarketSite NASDAQ MarketSite (or simply MarketSite) is the physical presence of the NASDAQ stock market. Located in Times Square in New York City, it occupies the bottom of the Condé Nast Building, located at 4 Times Square. in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , starting at 10:00 a.m. (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ). The meeting will feature presentations by members of the senior management team including Kevin King (CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. ), John Batty (CFO See Chief Financial Officer. ) and Jay Kaufman (VP, Marketing) who will outline the company's strategic priorities, growth initiatives and new product plans. The event will also include presentations from two of the company's customers that highlight advances in high-resolution genetic analysis and FDA-approved diagnostic tests that use Affymetrix technologies. Due to space limitations, attendance at the event is by invitation only. Affymetrix will be webcasting the event and interested parties may listen to a live broadcast of the meeting on the company's website, www.affymetrix.com, by clicking on "About Affymetrix/Investors." An audio archive of the Webcast will be available in the Investors section of our website through Tuesday, June 30, 2009. About Affymetrix Affymetrix GeneChip([R])microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research. They enable scientists to develop diagnostics which may support the tailoring of treatments for patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 17,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. ; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other risk factors are discussed in Affymetrix' Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip([R]) are registered trademarks owned or used by Affymetrix Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion